Objective XCellR8 Limited aims to offer the first completely animal-free test for human acute toxicity. The primary focus is cosmetic product safety but the test may also later be applied to other industry sectors including household products, agrochemicals, medical devices and pharmaceuticals. In this context, animal-free means in vitro human cell culture based methods that do not utilise any animal-derived components. There are currently no validated in vitro tests for acute toxicity. Previous attempts to develop such tests used mouse cells and animal-derived components in the culture system and therefore still ultimately required the sacrifice of animals – an approach that is not considered acceptable by ethical cosmetic companies or by the public. The technological feasibility of the project has already been established, through existing tests of XCellR8’s internally developed proprietary methods. This feasibility assessment project is primarily required to address other practical, commercial, regulatory and financial aspects. It will also expand existing market research to assess the appetite of a greater cross-section of industry for such tests. During the project XCellR8 will investigate the alternative routes for test development and adoption by industry as a non-regulatory test to support product development. The ultimate objective is the international validation of the test and regulatory acceptance via incorporation into OECD Guidelines. The proposed project constitutes scientific advancement, using a fully human based method to assess human safety, as well as providing ethical, financial and commercial advantages over the use of animal tests. This offers true SME business model innovation, with an SME creating a pioneering solution that could bring a fundamental change to the manner in which cosmetic companies (and their suppliers) validate the safety of the ingredients used in their products. Fields of science agricultural sciencesagriculture, forestry, and fisheriesagricultureagronomyplant protectionmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugssocial scienceseconomics and businessbusiness and managementbusiness modelssocial sciencespolitical sciencesgovernment systems Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator XCELLR8 LIMITED Net EU contribution € 50 000,00 Address THE INNOVATION CENTRE SCI-TECH DARESBURY KECKWICK WA4 4FS DARESBURY United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region North West (England) Merseyside East Merseyside Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00